.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Moodys
Chubb
Mallinckrodt
Julphar
McKinsey
Queensland Health
Teva
US Army
Federal Trade Commission

Generated: September 21, 2017

DrugPatentWatch Database Preview

DELZICOL Drug Profile

« Back to Dashboard

Which patents cover Delzicol, and what generic Delzicol alternatives are available?

Delzicol is a drug marketed by Apil and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in five countries.

The generic ingredient in DELZICOL is mesalamine. There are twenty-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Summary for Tradename: DELZICOL

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list112
Clinical Trials: see list1
Patent Applications: see list6,047
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DELZICOL at DailyMed

Pharmacology for Tradename: DELZICOL

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412-001Feb 1, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DELZICOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412-001Feb 1, 2013► Subscribe► Subscribe
Apil
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412-001Feb 1, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DELZICOL

Drugname Dosage Strength RLD Submissiondate
mesalamineDelayed-release Capsules400 mgDelzicol6/17/2014

International Patent Family for Tradename: DELZICOL

Country Document Number Estimated Expiration
Spain2191595► Subscribe
South Korea100536084► Subscribe
Japan3716901► Subscribe
European Patent Office1045000► Subscribe
South Korea20010014728► Subscribe
Japan2000297102► Subscribe
Germany60001283► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Mallinckrodt
Baxter
Cantor Fitzgerald
Dow
Johnson and Johnson
Moodys
Deloitte
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot